These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15668292)

  • 1. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity?
    Sebagh M; Plasse M; Lévi F; Adam R
    Ann Oncol; 2005 Feb; 16(2):331; author reply 332-3. PubMed ID: 15668292
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Rubbia-Brandt L; Audard V; Sartoretti P; Roth AD; Brezault C; Le Charpentier M; Dousset B; Morel P; Soubrane O; Chaussade S; Mentha G; Terris B
    Ann Oncol; 2004 Mar; 15(3):460-6. PubMed ID: 14998849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases.
    Rubbia-Brandt L; Mentha G; Terris B
    J Am Coll Surg; 2006 Jan; 202(1):199-200. PubMed ID: 16377516
    [No Abstract]   [Full Text] [Related]  

  • 4. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy.
    Seo AN; Kim H
    Clin Mol Hepatol; 2014 Mar; 20(1):81-4. PubMed ID: 24757663
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic veno-occlusive disease after neoadjuvant treatment of colorectal liver metastases with oxaliplatin: a lesson of the month.
    Schouten van der Velden AP; Punt CJ; Van Krieken JH; Derleyn VA; Ruers TJ
    Eur J Surg Oncol; 2008 Mar; 34(3):353-5. PubMed ID: 17207961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
    Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
    AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
    Overman MJ; Maru DM; Charnsangavej C; Loyer EM; Wang H; Pathak P; Eng C; Hoff PM; Vauthey JN; Wolff RA; Kopetz S
    J Clin Oncol; 2010 May; 28(15):2549-55. PubMed ID: 20406923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
    Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
    PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.
    Park S; Kim HY; Kim H; Park JH; Kim JH; Kim KH; Kim W; Choi IS; Jung YJ; Kim JS
    Medicine (Baltimore); 2016 Jan; 95(2):e2454. PubMed ID: 26765438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
    Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
    Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases.
    Robinson SM; White SA
    Histopathology; 2012 Dec; 61(6):1247-8. PubMed ID: 23043422
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxaliplatin toxicity presenting as a liver nodule - case report.
    Alexandrino H; Oliveira D; Cipriano MA; Ferreira L; Tralhão JG; Castro E Sousa F
    BMC Cancer; 2015 Apr; 15():247. PubMed ID: 25886004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinusoidal obstruction syndrome (SOS): A light and electron microscopy study in human liver.
    Vreuls CP; Driessen A; Olde Damink SW; Koek GH; Duimel H; van den Broek MA; Dejong CH; Braet F; Wisse E
    Micron; 2016 May; 84():17-22. PubMed ID: 26914502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome.
    Schiffer E; Frossard JL; Rubbia-Brandt L; Mentha G; Pastor CM
    J Surg Oncol; 2009 Jun; 99(7):439-46. PubMed ID: 19353590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
    J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
    Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
    Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
    Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.